

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Present Application:

Applicants : Corinna Herrnsstadt *et al.*
Title : *DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS FOR ALZHEIMER'S DISEASE*
Docket No. : 660088.401C9
Date : October 15, 2001

Prior Application:

Examiner : James Ketter
Art Unit : 1636
Application No. : 09/448,312

Box Patent Application
Commissioner for Patents
Washington, DC 20231

REMARKS

Commissioner for Patents:

The above-identified application is a continuation of co-pending U.S. Patent Application No. 09/448,312, filed November 23, 1999, now allowed; which is a continuation of U.S. Patent Application No. 08/413,740, filed March 30, 1995 and issued as U.S. Patent No. 6,171,859 on January 9, 2001; which is a continuation-in-part of U.S. Patent Application No. 08/219,842 filed March 30, 1994, and issued as U.S. Patent No. 5,565,323; to which priority is claimed under 35 U.S.C. §120.

The related applications paragraph has been revised to include the parent application and the issued U.S. Patent Nos. 6,171,859 and 5,565,323.

Please note that the instant application retains the title as originally filed in the parent application, U.S. Patent Application No. 09/448,312, filed November 23, 1999: "DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS FOR ALZHEIMERS DISEASE,"

which title was amended in the parent application to "Method of Targeting Conjugate Molecules to Mitochondria" during its prosecution.

The specification has been revised to incorporate amendments entered in the parent application. Typographical errors have been corrected as noted in the hand-written changes which appear on the parent U.S. Patent Application No. 09/448,312, as originally filed on November 23, 1999.

The specification has also been revised to correct the following typographical errors:

On page 2, line 24, the numbers "1303" immediately following "*Neurology* 40:1302" have been deleted.

On page 21, line 12, "complementarily" has been changed to "complementarity".

On page 22, line 12, "to be assigned" has been replaced by "08/410,658".

On page 58, line 20 has been changed as follows: "of 0.1, 0.33, 1, 3.3, and 10 μM .
These are incubated for 15 minutes then applied to the cell".

With regard to the claims, claims 1-20 and 32-43 have been omitted. Accordingly, the claims have been renumbered sequentially and, therefore, claims 1-11 are currently pending. No new matter has been added.

Applicants have filed herewith a Request To Use Computer Readable Form from Parent Application. The paper copy of the Sequence Listing filed herewith is identical to the computer readable copy filed in the priority applications noted therein.

CONCLUSION

In view of the state of the art at the time of filing of the priority application as disclosed in the Specification and recited in Claims 1-11, the present application complies with the requirements of 35 U.S.C. §112. Accordingly, the present application teaches a person of

ordinary skill in the art how to readily make and use, without undue experimentation, compositions and methods suitable for detecting and treating Alzheimer's disease. The claims are therefore in condition for allowance.

If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to telephone the undersigned at (206) 622-4900.



00500

PATENT TRADEMARK OFFICE

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Jeffrey C. Pepe, Ph.D.
Registration No. 46,985

JCP:Imp

Phone: (206) 622-4900

Fax: (206) 682-6031

221142